System of Objectified Judgement Analysis (SOJA) as a tool in rational and transparent drug-decision making

Abstract

Drug selection should be a rational process that embraces the principles of evidence-based medicine. However, many factors may affect the choice of agent. It is against this background that the System of Objectified Judgement Analysis (SOJA) process for rational drug-selection was developed. This article describes how the information on which the SOJA process is based, was researched and processed.

Integrated medicines management to medicines optimisation in Northern Ireland (2000–2014): a review

“…This was based on a decision analysis matrix model for medicines namely the System of Objectified Judgement Analysis and Informatrix 29. This system is now fully web based and also uses e-sessions to maximise clinician engagement.…”

Biosimilars of low molecular weight heparins: Relevant background information for your drug formulary

“…Dutch clinical pharmacists and researchers from Queens University of Belfast made a model for formulary decision that is applicable for choices within a therapeutic group e.g. different LMWHs and/or different biosimilar LMWHs: System of Objectified Judgment Analysis and the Infomatrix method: http://www.sojaonline.com …”

“…different LMWHs and/or different biosimilar LMWHs: System of Objectified Judgment Analysis and the Infomatrix method: www.sojaonline.com. [38][39][40] This model has proven to fulfil criteria for drug selection in the formulary uptake process and for pharmacy benefit managers and payers. Table 3 shows an example of key factors and weight factors that have to be determined and approved by voting in advance by the Pharmacy and Therapeutic committee members.…”

Current challenges in European oncology pharmacy practice

“…The System of Objectified Judgment Analysis (SOJA) assigned weighted values to emotional criteria, 39 with a panel of experts prospectively determining the relative importance of eight general decision-making criteria and a variable number of drug-class-specific criteria. Efficacy, safety, and acquisition cost usually comprise around 60% of the score, but this percentage can vary between groups of drugs (i.e., the panel gave these characteristics 72% of the weight of the score for nonsteroidal anti-inflammatory drugs and 50% of the weight of the score for antibiotics used in lower respiratory tract infections).…”